Efficacy of Anti–PD-1 Therapy and/or Ipilimumab in Acral Melanoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Efficacy of anti-PD-1 and ipilimumab alone or in combination in acral melanoma
J Immunother Cancer 2022 Jul 01;10(7)e004668, P Bhave, T Ahmed, SN Lo, A Shoushtari, A Zaremba, JM Versluis, J Mangana, M Weichenthal, L Si, T Lesimple, C Robert, C Trojanello, A Wicky, R Heywood, L Tran, K Batty, F Dimitriou, A Stansfeld, C Allayous, JK Schwarze, MJ Mooradian, O Klein, I Mehmi, R Roberts-Thomson, A Maurichi, HL Yeoh, A Khattak, L Zimmer, CU Blank, E Ramelyte, KC Kähler, S Roy, PA Ascierto, O Michielin, PC Lorigan, DB Johnson, R Plummer, C Lebbe, B Neyns, R Sullivan, O Hamid, M Santinami, GA McArthur, AM Haydon, GV Long, AM Menzies, MS CarlinoFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.